1. Getting to Grips With the Science of CGRP and Migraine

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. CGRP Is Involved in the Pathophysiology of Migraine

4. Treatments Targeting the CGRP Pathway

5. Trial Results: Small Molecules

6. Trial Results: mAbs

7. mAbs vs Current Preventive Therapy for Migraine

8. Gepants vs Current Acute Therapy of Migraine With Triptans

9. FDA Status of mAbs

10. Secondary Endpoints in Phase 3 CGRP Trials for Migraine Prevention: 50% Responder Rate

11. Secondary Endpoints in Phase 3 CGRP Trials for Migraine Prevention: 75% Responder Rate

12. Latest Data on Migraine Prevention

13. Clinical Application of mAbs

14. Abbreviations